Found 141 Neoplasms trials
A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is a Phase 1, multiple-dose, ascending dose-escalation and expansion study of XmAb22841, both as a monotherapy and in combination with pembrolizumab. The study is designed in 2 parts, Part A and Part B. Part A is a 3 + 3 dose escalation designed to assess both XmAb22841 administered as …
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere …
To determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 …
Primary: To determine the preliminary efficacy of TATE in the locoregional treatment of NET liver metastases using ORR based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 and the DoR. Secondary: Determine the toxicity of TATE in NET patients with liver-dominant metastases Determine the PFS by mRECIST and …
The purpose of this study is to test the study drug, PC14586 alone and in combination with pembrolizumab in patients with an advanced solid tumor with a TP53 Y220C alteration who have gone through one or more anticancer therapies and are not responding. PC14586 will be tested at different doses …
Please refer to Protocol Section 5 (Trial Objectives) Please refer to Protocol 6.2.1 (Phase 1 Primary Endpoints) and Protocol Section 6.2.4 (Phase 2 Primary Endpoints) Please refer to Protocol 6.2.2 (Phase 1 Secondary Endpoint) and Protocol Section 6.2.5 (Phase 2 Secondary Endpoints)
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or …
This is a first-in-human (FIH), open label Phase 1/1b study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biologically relevant doses (OBRD) and the maximum tolerated dose (MTD) of MBRC-101 at one 1 or more dosing regimens. Phase 1b will evaluate …
Evaluate the effectiveness of Eye90 treatment in subjects with unresectable HCC. Incidence of adverse events (AEs), grouped by System Organ Class (SOC) and Preferred Term (PT), relatedness to study treatment/procedure, and severity. Incidence of serious adverse events (SAEs), grouped by System Organ Class (SOC) and Preferred Term (PT), relatedness to …
This study compares the impact of using a combination of drugs, ramucirumab and pembrolizumab, versus standard chemotherapy for treating advanced non-small cell lung cancer that is stage IV or recurrent. Ramucirumab blocks new blood vessel growth that tumors need, while pembrolizumab boosts the immune system to fight cancer. The trial …
